Organon & Co. (NYSE:OGN) Shares Bought by American Century Companies Inc.

American Century Companies Inc. boosted its holdings in shares of Organon & Co. (NYSE:OGN) by 4.3% during the fourth quarter, HoldingsChannel.com reports. The firm owned 42,948 shares of the company’s stock after purchasing an additional 1,777 shares during the period. American Century Companies Inc.’s holdings in Organon & Co. were worth $641,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Verition Fund Management LLC purchased a new position in shares of Organon & Co. during the 3rd quarter valued at approximately $195,000. Quantinno Capital Management LP raised its position in Organon & Co. by 65.1% during the third quarter. Quantinno Capital Management LP now owns 18,385 shares of the company’s stock worth $352,000 after acquiring an additional 7,252 shares during the period. Stifel Financial Corp lifted its holdings in Organon & Co. by 13.6% during the third quarter. Stifel Financial Corp now owns 236,081 shares of the company’s stock valued at $4,516,000 after purchasing an additional 28,344 shares in the last quarter. Wellington Management Group LLP purchased a new position in Organon & Co. during the third quarter valued at $437,000. Finally, Kovitz Investment Group Partners LLC grew its position in shares of Organon & Co. by 93.4% in the third quarter. Kovitz Investment Group Partners LLC now owns 23,027 shares of the company’s stock valued at $441,000 after purchasing an additional 11,119 shares during the period. 77.43% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OGN has been the subject of several research analyst reports. Barclays reduced their price target on shares of Organon & Co. from $26.00 to $24.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. TD Cowen upgraded Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th. Finally, Morgan Stanley decreased their target price on Organon & Co. from $16.00 to $15.00 and set an “equal weight” rating on the stock in a research report on Wednesday. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $20.60.

Organon & Co. Stock Performance

OGN opened at $11.17 on Friday. Organon & Co. has a twelve month low of $10.94 and a twelve month high of $23.10. The firm has a market capitalization of $2.88 billion, a PE ratio of 3.35, a PEG ratio of 0.90 and a beta of 0.73. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73. The firm’s 50-day moving average price is $14.64 and its 200 day moving average price is $15.67.

Organon & Co. (NYSE:OGN) last released its earnings results on Thursday, February 13th. The company reported $0.83 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.09). The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. As a group, sell-side analysts expect that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 13th. Shareholders of record on Monday, February 24th were paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 10.03%. The ex-dividend date was Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.